For those of a gambling nature, it would not be surprising to see demand on the buy side to increase prior to the May 7 presentation. If Isradapine works to slow the progression of Parkinson's, the news will generate nationwide exposure to the drug as well as Elite. If results are negative, many current stockholders may look to get out which would serve as a buying opportunity for true believers. In any event, I think there will be high volume and volatility next week.
Market Data 
Markets 
AI
